Quince Therapeutics, Inc. (QNCX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Current obligations | 8.50M USD | Liabilities, Current |
| Cash and equivalents | 115.98M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 0.00 USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $8.50M | $115.98M | $0.00 | (m) | (m) | (m) |
| 2026-03-31 | (m) | $8.77M | $18.16M | $0.00 | (m) | (m) | (m) |
| 2025-12-31 | (m) | $43.23M | $5.81M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $26.04M | $6.45M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $7.47M | $16.83M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $8.36M | $7.77M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $7.28M | (m) | $34.57M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $5.42M | (m) | $45.17M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $10.32M | (m) | $51.55M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $9.84M | (m) | $46.01M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $9.57M | (m) | $54.31M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $2.25M | $20.82M | $61.59M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $1.95M | $20.62M | $64.92M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $3.12M | $42.27M | $43.49M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $3.07M | (m) | $45.60M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $4.95M | $21.58M | $62.53M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $5.95M | $33.53M | $47.74M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $9.71M | $40.16M | $23.96M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $14.22M | (m) | $37.08M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $14.15M | (m) | $52.20M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $18.54M | (m) | $55.90M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $17.87M | (m) | $61.72M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $17.00M | (m) | $66.98M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $16.41M | $64.25M | $73.55M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $13.69M | $66.16M | $78.35M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $13.11M | $85.61M | $76.81M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $8.89M | $51.21M | $48.65M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $6.13M | $44.74M | $75.73M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $7.03M | $44.31M | $83.97M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $4.01M | $20.63M | $38.41M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $1.46M | $24.87M | $46.84M | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $27.29M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $77.47M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $4.40M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |